LifeVantage (LFVN) Q1 2025 earnings summary

Executive summary

• Q1 FY2025 revenue was $47.2 million, down 8.1% year-over-year, with declines in both Americas and Asia/Pacific & Europe regions.

• Net income rose to $1.8 million from $0.6 million, driven by lower operating expenses and cost optimization.

• Adjusted EBITDA increased 11% to $4.4 million, with margin up 160 basis points.

• Active accounts declined 10.2% year-over-year, reflecting lower numbers of both independent consultants and customers.

• Launched MindBody GLP-1 System, expanding the addressable market and driving overwhelming initial demand.

Financial highlights

• Gross margin was 79.9%, slightly below the prior year's 80.2%.

• Adjusted non-GAAP net income was $1.9 million ($0.15 per diluted share), up from $1.7 million ($0.13 per share) last year.

• Operating income rose to $2.6 million from $0.7 million, as SG&A expenses fell.

• Commissions and incentives expense was 43.0% of revenue, down from 43.8%.

• Cash and cash equivalents totaled $14.6 million at quarter end, with no debt outstanding.

Outlook and guidance

• FY2025 revenue expected between $200 million–$210 million, likely at the upper end due to MindBody demand.

• Adjusted EBITDA projected at $18 million–$21 million; adjusted EPS expected at $0.70–$0.80.

• Full-year tax rate projected at 25%–27%.

• Cash and cash equivalents, along with ongoing cash flow, are expected to be sufficient for at least the next 12 months.

• Long-term target for adjusted EBITDA margin remains in the low double digits.